Search

Your search keyword '"Habicht, Antje"' showing total 193 results
Start Over Author "Habicht, Antje"
193 results on '"Habicht, Antje"'

1. Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial

Author

Gwinner, Wilfried, Karch, Annika, Braesen, Jan H., Khalifa, Abedalrazag A., Metzger, Jochen, Naesens, Maarten, Van Loon, Elisabet, Anglicheau, Dany, Marquet, Pierre, Budde, Klemens, Matz, Mareen, Arns, Wolfgang, Fischereder, Michael, Habicht, Antje, Eisenberger, Ute, Mühlfeld, Anja, Busch, Martin, Wiesener, Michael, Scheffner, Irina, and Koch, Armin

Published
2022
Full Text
View/download PDF

5. Clinical Validation of a Novel ELISpot-based in Vitro Diagnostic Assay to Monitor CMV-specific Cell-Mediated Immunity in Kidney Transplant Recipients

Author

Banas, Bernhard, Steubl, Dominik, Renders, Lutz, Chittka, Dominik, Banas, Miriam C., Wekerle, Thomas, Koch, Martina, Witzke, Oliver, Mühlfeld, Anja, Sommerer, Claudia, Habicht, Antje, Hugo, Christian, Huenig, Thomas, Lindemann, Monika, Schmidt, Traudel, Rascle, Anne, Barabas, Sascha, Deml, Ludwig, Wagner, Ralf, Kraemer, Bernhard K., and Krueger, Bernd

Published
2018
Full Text
View/download PDF

7. WATER AND SALT

Author

Fischereder, Michael, Michalke, Bernhard, Schmoeckel, Elisa, Habicht, Antje, Szabados, Bernadett, Nelson, Peter J, and Stangl, Manfred

Published
2014

9. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model

Author

Ueno, Takuya, Habicht, Antje, Clarkson, Michael R., Albin, Monica J., Yamaura, Kazuhiro, Boenisch, Olaf, Popoola, Joyce, Wang, Ying, Yagita, Hideo, Akiba, Hisaya, Ansari, M. Javeed, Yang, Jaeseok, Turka, Laurence A., Rothstein, David M., Padera, Robert F., Najafian, Nader, and Sayegh, Mohamed H.

Subjects
Mucins -- Health aspects, Mucins -- Genetic aspects, Mucins -- Research, T cell proliferation -- Health aspects, T cell proliferation -- Methods, T cell proliferation -- Research, Immune response -- Health aspects, Immune response -- Research
Abstract

T cell Ig mucin 1 (TIM-1) plays an important role in regulating immune responses in autoimmune and asthma models, and it is expressed on both Th1 and Th2 cells. Using an antagonistic TIM-1-specific antibody, we studied the role of TIM-1 in alloimmunity. A short course of TIM-1-specific antibody monotherapy prolonged survival of fully MHC-mismatched vascularized mouse cardiac allografts. This prolongation was associated with inhibition of alloreactive Th1 responses and preservation of Th2 responses. TIM-1-specific antibody treatment was more effective in Th1-type cytokine--deficient Stat4-/- recipients as compared with Th2-type cytokine--deficient Stat6-/- recipients. Subtherapeutic doses of rapamycin plus TIM-1-specific antibody resulted in allograft acceptance and prevented the development of chronic allograft vasculopathy. Allograft survival via this treatment was accompanied by a Th1- to Th2-type cytokine switch. Depletion of natural Tregs abrogated the graft-protecting effect of the TIM-1-specific antibody. Importantly, [CD4.sup.+][CD25.sup.+] Tregs obtained from long-term survivors had enhanced regulatory activity as compared with naive [CD4.sup.+][CD25.sup.+] Tregs. Consistent with this, TIM-1-specific antibody treatment both preserved Tregs and prevented the expansion of alloreactive effector Th1 cells in an alloreactive TCR transgenic adoptive transfer model. These studies define previously unknown functions of TIM-1 in regulating alloimmune responses in vivo and may provide a novel approach to promoting transplantation tolerance., Introduction The T cell Ig mucin (TIM) family of genes encodes proteins that are expressed by T cells and contain an IgV-like and a mucin-like domain (1). The TIM family [...]

Published
2008

10. Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange

Author

Sagmeister, Michael S., Weiss, Max, Eichhorn, Peter, Habicht, Antje, Habersetzer, Rupert, Fischereder, Michael, and Schönermarck, Ulf

Subjects
Vasculitis, de novo, Plasma Exchange, ANCA, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, Combined Modality Therapy, Kidney transplantation, Case report, Humans, Immunologic Factors, Female, Rituximab, Aged
Abstract

Background Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis causes end-stage renal failure in up to a third of cases even with treatment. The disease recurs occasionally after kidney transplantation, but new onset of ANCA-associated vasculitis after transplantation is highly unusual. The use of rituximab or plasmapheresis for de novo disease after transplantation has not previously been reported. Case presentation Routine post-transplant follow-up for a 66-year old asymptomatic woman revealed a rise in creatinine from 1.8 to 2.6 mg/dl and increased proteinuria. She had received a cadaveric kidney transplant 20 months previously for end-stage autosomal dominant polycystic kidney disease. Renal allograft biopsy unexpectedly demonstrated pauci-immune glomerulonephritis with extracapillary proliferation and interstitial inflammation. Concurrent serum tested strongly positive for ANCA specific to proteinase 3 (PR3), but stored pre- and post-transplantation serum samples tested negative. These findings established a diagnosis of de novo ANCA-associated vasculitis in the renal allograft. We started treatment with high-dose corticosteroid and rituximab. Despite this, serum creatinine continued to rise and glomerulonephritis remained active in a repeat biopsy. Escalation of the treatment with seven sessions of plasmapheresis led to a temporary improvement in creatinine. No further features of vasculitis emerged and PR3-ANCA titres declined. However, multiple infections complicated the recovery period and were associated with progressive loss of renal transplant function. Four months after the index presentation, transplant function became insufficient and dialysis was restarted. Conclusions De novo ANCA-associated vasculitis after renal transplantation is exceptionally rare. It poses a significant risk to graft survival even in the context of intensified immunosuppression. Management relies on clinical evidence from populations with native renal function, yet post-transplant patients may be at increased risk of treatment-related adverse events. Precautions against these risks are crucial in the delivery of care.

Published
2018

19. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study

Author

Ziemann, Malte, Altermann, Wolfgang, Angert, Katharina, Arns, Wolfgang, Bachmann, Anette, Bakchoul, Tamam, Banas, Bernhard, von Borstel, Annette, Budde, Klemens, Ditt, Vanessa, Einecke, Gunilla, Eisenberger, Ute, Feldkamp, Thorsten, Goerg, Siegfried, Guthoff, Martina, Habicht, Antje, Hallensleben, Michael, Heinemann, Falko M., Hessler, Nicole, Hugo, Christian, Kaufmann, Matthias, Kauke, Teresa, Koch, Martina, Koenig, Inke R., Kurschat, Christine, Lehmann, Claudia, Marget, Matthias, Muehlfeld, Anja, Nitschke, Martin, da Silva, Luiza Pego, Quick, Carmen, Rahmel, Axel, Rath, Thomas, Reinke, Petra, Renders, Lutz, Sommer, Florian, Spriewald, Bernd, Staeck, Oliver, Stippel, Dirk, Suesal, Caner, Thiele, Bernhard, Zecher, Daniel, Lachmann, Nils, Ziemann, Malte, Altermann, Wolfgang, Angert, Katharina, Arns, Wolfgang, Bachmann, Anette, Bakchoul, Tamam, Banas, Bernhard, von Borstel, Annette, Budde, Klemens, Ditt, Vanessa, Einecke, Gunilla, Eisenberger, Ute, Feldkamp, Thorsten, Goerg, Siegfried, Guthoff, Martina, Habicht, Antje, Hallensleben, Michael, Heinemann, Falko M., Hessler, Nicole, Hugo, Christian, Kaufmann, Matthias, Kauke, Teresa, Koch, Martina, Koenig, Inke R., Kurschat, Christine, Lehmann, Claudia, Marget, Matthias, Muehlfeld, Anja, Nitschke, Martin, da Silva, Luiza Pego, Quick, Carmen, Rahmel, Axel, Rath, Thomas, Reinke, Petra, Renders, Lutz, Sommer, Florian, Spriewald, Bernd, Staeck, Oliver, Stippel, Dirk, Suesal, Caner, Thiele, Bernhard, Zecher, Daniel, and Lachmann, Nils

Abstract

Background and objectivesThe prognostic value of preformed donor-specific HLA antibodies (DSA), which are only detectable by sensitive methods, remains controversial for kidney transplantation.Design, setting, participants, & measurementsThe outcome of 4233 consecutive kidney transplants performed between 2012 and 2015 in 18 German transplant centers was evaluated. Most centers used a stepwise pretransplant antibody screening with bead array tests and differentiation of positive samples by single antigen assays. Using these screening results, DSA against HLA-A, -B, -C, -DRB1 and -DQB1 were determined. Data on clinical outcome and possible covariates were collected retrospectively.ResultsPretransplant DSA were associated with lower overall graft survival, with a hazard ratio of 2.53 for living donation (95% confidence interval [95% CI], 1.49 to 4.29; P<0.001) and 1.59 for deceased donation (95% CI, 1.21 to 2.11; P=0.001). ABO-incompatible transplantation was associated with worse graft survival (hazard ratio, 2.09; 95% CI, 1.33 to 3.27; P=0.001) independent from DSA. There was no difference between DSA against class 1, class 2, or both. Stratification into DSA <3000 medium fluorescence intensity (MFI) and DSA >= 3000 MFI resulted in overlapping survival curves. Therefore, separate analyses were performed for 3-month and long-term graft survival. Although DSA <3000 MFI tended to be associated with both lower 3-month and long-term transplant survival in deceased donation, DSA >= 3000 MFI were only associated with worse long-term transplant survival in deceased donation. In living donation, only strong DSA were associated with reduced graft survival in the first 3 months, but both weak and strong DSA were associated with reduced long-term graft survival. A higher incidence of antibody-mediated rejection within 6 months was only associated with DSA >= 3000 MFI.ConclusionsPreformed DSA were associated with an increased risk for graft loss in kidney transplantation, which

Published
2019

23. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation

Author

Ziemann, Malte, primary, Altermann, Wolfgang, additional, Angert, Katharina, additional, Arns, Wolfgang, additional, Bachmann, Anette, additional, Bakchoul, Tamam, additional, Banas, Bernhard, additional, von Borstel, Annette, additional, Budde, Klemens, additional, Ditt, Vanessa, additional, Einecke, Gunilla, additional, Eisenberger, Ute, additional, Feldkamp, Thorsten, additional, Görg, Siegfried, additional, Guthoff, Martina, additional, Habicht, Antje, additional, Hallensleben, Michael, additional, Heinemann, Falko M., additional, Hessler, Nicole, additional, Hugo, Christian, additional, Kaufmann, Matthias, additional, Kauke, Teresa, additional, Koch, Martina, additional, König, Inke R., additional, Kurschat, Christine, additional, Lehmann, Claudia, additional, Marget, Matthias, additional, Mühlfeld, Anja, additional, Nitschke, Martin, additional, Pego da Silva, Luiza, additional, Quick, Carmen, additional, Rahmel, Axel, additional, Rath, Thomas, additional, Reinke, Petra, additional, Renders, Lutz, additional, Sommer, Florian, additional, Spriewald, Bernd, additional, Staeck, Oliver, additional, Stippel, Dirk, additional, Süsal, Caner, additional, Thiele, Bernhard, additional, Zecher, Daniel, additional, and Lachmann, Nils, additional

Published
2019
Full Text
View/download PDF

26. Early conversion to a CNI-free immunosuppression with SRL after renal transplantation—Long-term follow-up of a multicenter trial.

Author

Andrassy, Joachim, Guba, Markus, Habicht, Antje, Fischereder, Michael, Pratschke, Johann, Pascher, Andreas, Heller, Katharina M., Banas, Bernhard, Hakenberg, Oliver, Vogel, Thomas, Meiser, Bruno, Dick, Andrea, Werner, Jens, and Kauke, Teresa

Subjects
IMMUNOSUPPRESSION, BLOOD sampling
Abstract

Introduction: Early conversion to a CNI-free immunosuppression with SRL was associated with an improved 1- and 3- yr renal function as compared with a CsA-based regimen in the SMART-Trial. Mixed results were reported on the occurrence of donor specific antibodies under mTOR-Is. Here, we present long-term results of the SMART-Trial. Methods and materials: N = 71 from 6 centers (n = 38 SRL and n = 33 CsA) of the original SMART-Trial (ITT n = 140) were enrolled in this observational, non-interventional extension study to collect retrospectively and prospectively follow-up data for the interval since baseline. Primary objective was the development of dnDSA. Blood samples were collected on average 8.7 years after transplantation. Results: Development of dnDSA was not different (SRL 5/38, 13.2% vs. CsA 9/33, 27.3%; P = 0.097). GFR remained improved under SRL with 64.37 ml/min/1.73m2 vs. 53.19 ml/min/1.73m2 (p = 0.044). Patient survival did not differ between groups at 10 years. There was a trend towards a reduced graft failure rate (11.6% SRL vs. 23.9% CsA, p = 0.064) and less tumors under SRL (2.6% SRL vs. 15.2% CsA, p = 0.09). Conclusions: An early conversion to SRL did not result in an increased incidence of dnDSA nor increased long-term risk for the recipient. Transplant function remains improved with benefits for the graft survival. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

27. Dynamic CTA in Native Kidneys Using a Multiphase CT Protocol—Potential of Significant Reduction of Contrast Medium

Author

Braunagel, Margarita, primary, Ortner, Florian, additional, Schönermarck, Ulf, additional, Habicht, Antje, additional, Schindler, Andreas, additional, Stangl, Manfred, additional, Strobl, Frederik F., additional, Reiser, Maximilian, additional, Clevert, Dirk A., additional, Trumm, Christoph, additional, and Helck, Andreas, additional

Published
2018
Full Text
View/download PDF

30. Clinical validation of a novel enzyme-linked immunosorbent spot assay-basedin vitrodiagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study

Author

Banas, Bernhard, primary, Steubl, Dominik, additional, Renders, Lutz, additional, Chittka, Dominik, additional, Banas, Miriam C., additional, Wekerle, Thomas, additional, Koch, Martina, additional, Witzke, Oliver, additional, Mühlfeld, Anja, additional, Sommerer, Claudia, additional, Habicht, Antje, additional, Hugo, Christian, additional, Hünig, Thomas, additional, Lindemann, Monika, additional, Schmidt, Traudel, additional, Rascle, Anne, additional, Barabas, Sascha, additional, Deml, Ludwig, additional, Wagner, Ralf, additional, Krämer, Bernhard K., additional, and Krüger, Bernd, additional

Published
2018
Full Text
View/download PDF

31. Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation

Author

Ziemann, Malte, Hessler, Nicole, Koenig, Inke R., Lachmann, Nils, Dick, Andrea, Ditt, Vanessa, Budde, Klemens, Reinke, Petra, Eisenberger, Ute, Suwelack, Barbara, Klein, Thomas, Westhoff, Timm H., Arns, Wolfgang, Ivens, Katrin, Habicht, Antje, Renders, Lutz, Stippel, Dirk, Boes, Dominik, Sommer, Florian, Goerg, Siegfried, Nitschke, Martin, Feldkamp, Thorsten, Heinemann, Falko M., Kelsch, Reinhard, Ziemann, Malte, Hessler, Nicole, Koenig, Inke R., Lachmann, Nils, Dick, Andrea, Ditt, Vanessa, Budde, Klemens, Reinke, Petra, Eisenberger, Ute, Suwelack, Barbara, Klein, Thomas, Westhoff, Timm H., Arns, Wolfgang, Ivens, Katrin, Habicht, Antje, Renders, Lutz, Stippel, Dirk, Boes, Dominik, Sommer, Florian, Goerg, Siegfried, Nitschke, Martin, Feldkamp, Thorsten, Heinemann, Falko M., and Kelsch, Reinhard

Abstract

Background. The assignment of human leucocyte antigens (HLAs) against which antibodies are detected as unacceptable antigens (UAGs) avoids allocation of HLA-incompatible allografts. There is uncertainty as to what extent UAGs decrease the probability of receiving a kidney offer. Methods. Kidney transplantations in 3264 patients on the waiting lists of six German transplant centres were evaluated for a period of at least 2 years. The proportion of excluded offers due to UAGs was calculated as virtual panel-reactive antibodies (vPRAs). Results. In the common Eurotransplant Kidney Allocation Scheme, the transplant probability was unaffected by vPRAs in exploratory univariate analyses. In the multivariable model, a 1% increase in vPRA values was outweighed by an additional waiting time of 2.5 weeks. The model was confirmed using an external validation cohort of 1521 patients from seven centres. If only patients with standard risk were considered (e.g. no simultaneous transplantation of other organs), only 1.3 weeks additional waiting time was needed. In the Eurotransplant Senior Program, patients with vPRA values >50% had a strongly reduced transplant probability in the unadjusted analyses. In the multivariable model, a 1% increase in vPRA values was outweighed by an additional waiting time of 5 weeks. Conclusions: This study demonstrates that the assignment of UAGs decreases the transplant probability in both main Eurotransplant allocation programs because of insufficient compensatory mechanisms. At present, for immunized patients, a prolonged waiting time has to be weighed against the increased immunologic risk due to donor-specific antibodies not assigned as UAGs.

Published
2017

34. MP315CLINICAL VALIDATION OF A NOVEL ELISPOT-BASED IN VITRO DIAGNOSTIC ASSAY TO MONITOR CMV-SPECIFIC CELL-MEDIATED IMMUNITY IN KIDNEY TRANSPLANT RECIPIENTS

Author

Banas, Bernhard, primary, Steubl, Dominik, additional, Renders, Lutz, additional, Chittka, Dominik, additional, Banas, Miriam, additional, Wekerle, Thomas, additional, Koch, Martina, additional, Witzke, Oliver, additional, Mühlfeld, Anja, additional, Sommerer, Claudia, additional, Habicht, Antje, additional, Hugo, Christian, additional, Hünig, Thomas, additional, Lindemann, Monika, additional, Schmidt, Traudel, additional, Rascle, Anne, additional, Barabas, Sascha, additional, Deml, Ludwig, additional, Wagner, Ralf, additional, Krämer, Bernhard, additional, and Krüger, Bernd, additional

Published
2017
Full Text
View/download PDF

35. Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation

Author

Ziemann, Malte, primary, Heßler, Nicole, additional, König, Inke R., additional, Lachmann, Nils, additional, Dick, Andrea, additional, Ditt, Vanessa, additional, Budde, Klemens, additional, Reinke, Petra, additional, Eisenberger, Ute, additional, Suwelack, Barbara, additional, Klein, Thomas, additional, Westhoff, Timm H., additional, Arns, Wolfgang, additional, Ivens, Katrin, additional, Habicht, Antje, additional, Renders, Lutz, additional, Stippel, Dirk, additional, Bös, Dominik, additional, Sommer, Florian, additional, Görg, Siegfried, additional, Nitschke, Martin, additional, Feldkamp, Thorsten, additional, Heinemann, Falko M., additional, and Kelsch, Reinhard, additional

Published
2017
Full Text
View/download PDF

36. Effects of Dopamine Donor Pretreatment on Graft Survival after Kidney Transplantation: A Randomized Trial

Author

Schnuelle, Peter, primary, Schmitt, Wilhelm H., additional, Weiss, Christel, additional, Habicht, Antje, additional, Renders, Lutz, additional, Zeier, Martin, additional, Drüschler, Felix, additional, Heller, Katharina, additional, Pisarski, Przemyslaw, additional, Banas, Bernhard, additional, Krämer, Bernhard K., additional, Jung, Matthias, additional, Lopau, Kai, additional, Olbricht, Christoph J., additional, Weihprecht, Horst, additional, Schenker, Peter, additional, De Fijter, Johan W., additional, Yard, Benito A., additional, and Benck, Urs, additional

Published
2017
Full Text
View/download PDF

37. De novodonor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability

Author

Kauke, Teresa, primary, Oberhauser, Cornelia, additional, Lin, Viviane, additional, Coenen, Michaela, additional, Fischereder, Michael, additional, Dick, Andrea, additional, Schoenermarck, Ulf, additional, Guba, Markus, additional, Andrassy, Joachim, additional, Werner, Jens, additional, Meiser, Bruno, additional, Angele, Martin, additional, Stangl, Manfred, additional, and Habicht, Antje, additional

Published
2017
Full Text
View/download PDF

38. Dynamic Contrast-Enhanced Computed Tomography

Author

Braunagel, Margarita, primary, Helck, Andreas, additional, Wagner, Anne, additional, Schupp, Nina, additional, Bröcker, Verena, additional, Reiser, Maximilian, additional, Notohamiprodjo, Mike, additional, Meiser, Bruno, additional, and Habicht, Antje, additional

Published
2016
Full Text
View/download PDF

40. Clinical validation of a novel enzyme‐linked immunosorbent spot assay‐based <italic>in vitro</italic> diagnostic assay to monitor cytomegalovirus‐specific cell‐mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study

Author

Banas, Bernhard, Steubl, Dominik, Renders, Lutz, Chittka, Dominik, Banas, Miriam C., Wekerle, Thomas, Koch, Martina, Witzke, Oliver, Mühlfeld, Anja, Sommerer, Claudia, Habicht, Antje, Hugo, Christian, Hünig, Thomas, Lindemann, Monika, Schmidt, Traudel, Rascle, Anne, Barabas, Sascha, Deml, Ludwig, Wagner, Ralf, and Krämer, Bernhard K.

Subjects
CYTOMEGALOVIRUSES, CELLULAR immunity, KIDNEY transplantation, ENZYME-linked immunosorbent assay, ANTIVIRAL agents, INTERLEUKINS
Abstract

Summary: Impaired cytomegalovirus (CMV)‐specific cell‐mediated immunity (CMV‐CMI) is a major cause of CMV reactivation and associated complications in solid‐organ transplantation. Reliably assessing CMV‐CMI is desirable to individually adjust antiviral and immunosuppressive therapy. This study aimed to evaluate the suitability of T‐Track® CMV, a novel IFN‐γ ELISpot assay based on the stimulation of peripheral blood mononuclear cells with pp65 and IE‐I CMV proteins, to monitor CMV‐CMI following kidney transplantation. A prospective longitudinal multicenter study was conducted in 86 intermediate‐risk renal transplant recipients. CMV‐CMI, CMV viral load, and clinical complications were monitored over 6 months post‐transplantation. Ninety‐five percent and 88–92% ELISpot assays were positive pre‐ and post‐transplantation, respectively. CMV‐specific response was reduced following immunosuppressive treatment and increased in patients with graft rejection, indicating the ability of the ELISpot assay to monitor patients' immunosuppressive state. Interestingly, median pp65‐specific response was ninefold higher in patients with self‐clearing viral load compared to antivirally treated patients prior to first viral load detection (P < 0.001), suggesting that reactivity to pp65 represents a potential immunocompetence marker. Altogether, T‐Track® CMV is a highly sensitive IFN‐γ ELISpot assay, suitable for the immunomonitoring of CMV‐seropositive renal transplant recipients, and with a potential use for the risk assessment of CMV‐related clinical complications (ClinicalTrials.gov Identifier: NCT02083042). [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

41. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort

Author

Schnitzler, Fabian, primary, Friedrich, Matthias, additional, Stallhofer, Johannes, additional, Schönermarck, Ulf, additional, Fischereder, Michael, additional, Habicht, Antje, additional, Karbalai, Nazanin, additional, Wolf, Christiane, additional, Angelberger, Marianne, additional, Olszak, Torsten, additional, Beigel, Florian, additional, Tillack, Cornelia, additional, Göke, Burkhard, additional, Zachoval, Reinhart, additional, Denk, Gerald, additional, Guba, Markus, additional, Rust, Christian, additional, Grüner, Norbert, additional, and Brand, Stephan, additional

Published
2015
Full Text
View/download PDF

42. Sodium storage in human tissues is mediated by glycosaminoglycan expression.

Author

Fischereder, Michael, Michalke, Bernhard, Schmöckel, Elisa, Habicht, Antje, Kunisch, Raphael, Pavelic, Ivana, Szabados, Bernadette, Schönermarck, Ulf, Nelson, Peter J., and Stangl, Manfred

Abstract

The current paradigm regarding sodium handling in animals and humans postulates that total body sodium is regulated predominately via regulation of extracellular volume. Active sodium storage independent of volume retention is thought to be negligible. However, studies in animals, hypertensive patients, and healthy humans suggest water-free storage of sodium in skin. We hypothesized that tissue sodium concentrations ([Na]T) found in humans vary and reflect regulation due to variable glycosaminoglycan content due to variable expression of XYLT-1. Twenty seven patients on dialysis and 21 living kidney transplant donors free of clinically detectable edema were studied. During surgery, abdominal skin, muscle, and arteries were biopsied. [Na]T was determined by inductively coupled plasma-optical emission spectrometry, semiquantitative glycosaminoglycan content with Alcian stain, and XYLT-1 expression by real-time PCR. [Na]T of arteries were ranging between 0.86 and 9.83 g/kg wet wt and were significantly higher in arteries (4.52 ± 1.82 g/kg) than in muscle (2.03 ± 1.41 g/kg; P < 0.001) or skin (3.24 ± 2.26 g/kg wet wt; P = 0.038). For individual patients [Na]T correlated for skin and arterial tissue (r = 0.440, P = 0.012). [Na]T also correlated significantly with blinded semiquantitative analysis of glycosaminoglycans staining (r = 0.588, P = 0.004). In arteries XYLT-1 expression was also correlated with [Na]T (r = 0.392, P = 0.003). Our data confirm highly variable [Na]T in human skin and muscle and extend this observation to [Na]T in human arteries. These data support the hypothesis of water-independent sodium storage via regulated glycosaminoglycan synthesis in human tissues, including arteries. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

43. De novo donor-specific anti- HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability.

Author

Kauke, Teresa, Oberhauser, Cornelia, Lin, Viviane, Coenen, Michaela, Fischereder, Michael, Dick, Andrea, Schoenermarck, Ulf, Guba, Markus, Andrassy, Joachim, Werner, Jens, Meiser, Bruno, Angele, Martin, Stangl, Manfred, and Habicht, Antje

Subjects
KIDNEY transplant complications, HOMOGRAFTS, HUMAN leucocytes, IMMUNOGLOBULINS, STANDARD deviations
Abstract

Many aspects of post-transplant monitoring of donor-specific ( DSA) and non-donor-specific ( nDSA) anti- HLA antibodies on renal allograft survival are still unclear. Differentiating them by their ability to bind C1q may offer a better risk assessment. We retrospectively investigated the clinical relevance of de novo C1q-binding anti- HLA antibodies on graft outcome in 611 renal transplant recipients. Acute rejection ( AR), renal function, and graft survival were assessed within a mean follow-up of 6.66 years. Post-transplant 6.5% patients developed de novo DSA and 11.5% de novo nDSA. DSA (60.0%; P < 0.0001) but not nDSA (34.1%, P = 0.4788) increased rate of AR as compared with controls (27.4%). C1q-binding anti- HLA antibodies did not alter rate of AR in both groups. Renal function was only significantly diminished in patients with DSAC1q+. However, DSA significantly impaired 5-year graft survival (65.2%; P < 0.0001) in comparison with nDSA (86.7%; P = 0.0054) and controls (90.7%). While graft survival did not differ between DSAC1q− and DSAC1q+ recipients, 5-year allograft survival was reduced in nDSAC1q+ (80.9%) versus nDSAC1q− (90.7%, P = 0.0251). De novo DSA independently of their ability to bind C1q are associated with diminished graft survival. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

45. Decompression of Inflammatory Edema along with Endothelial Cell Therapy Expedites Regeneration after Renal Ischemia-Reperfusion Injury

Author

Herrler, Tanja, primary, Wang, Hao, additional, Tischer, Anne, additional, Schupp, Nina, additional, Lehner, Sebastian, additional, Meyer, Andreas, additional, Wallmichrath, Jens, additional, Habicht, Antje, additional, Mfarrej, Bechara, additional, Anders, Hans-Joachim, additional, Bartenstein, Peter, additional, Jauch, Karl-Walter, additional, Hacker, Marcus, additional, and Guba, Markus, additional

Published
2013
Full Text
View/download PDF

49. The TIM-1

Author

Rong, Song, primary, Park, Joon-Keun, additional, Kirsch, Torsten, additional, Yagita, Hideo, additional, Akiba, Hisaya, additional, Boenisch, Olaf, additional, Haller, Hermann, additional, Najafian, Nader, additional, and Habicht, Antje, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results